DICE Stock Price, Chart, Stats & News
DICE Therapeutics, Inc. (DICE) does not currently pay a dividend.
DICE chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 2.65% |
ROA | -13.75% |
ROE | 56.07% |
D/E | -0.07x |
Interest coverage ratio | -129.93x |
DICE valuation
P/E | – |
P/S | – |
P/B | -9.99x |
P/CF | -29.13x |
P/FCF | -34.12x |
P/OCF | -29.13x |
PEG | -0.23x |
EV multiple | -32.75x |
About
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications.
Similar securities
Based on sector and market capitalization
